Angion Biomedica Corporation

Decode Genetics Ehf

Advanced Life Sciences, Inc.

Medichem Research, Inc.

Northwestern University

David E Zembower

David A Eiznhamer

Jasbir Singh

Michael T Flavin

Yuh-Meei Lin

Mark E Gurney

Nian E Zhou

Peng Yu

Gen-Xian Zhao

Ralph Schure

Wayne Edward Zeller

Yongping Xie

Rama K Mishra

Rishi R Arora

Siead Zegar

Ralph M Schure

Livia A Enache

Yasheen Zhou

Geng-Xian Zhao

Christopher J Tokar

Heping Zhang

Alexandre Mikhaylovich Polozov

David Einzhamer

The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor antagonists (e.g., M2-selective muscarinic receptor blockers), administered alone or in combination with other therapeutic agents (e.g., beta-adrenergic receptor blockers) to treat and/or prevent atrial fibrillation.

Compositions and methods for treating or preventing atrial fibrillation

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R, Rand B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role.

Pyrazole derivatives as modulators of hepatocyte growth factor (scatter factor) activity

The present invention provides compounds having formula (I): 

Small molecule modulators of hepatocyte growth factor (scatter factor) activity

Peri-substituted, fused bicyclic ring carboxylic acids useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is: 

Carboxylic acid peri-substituted bicyclics for occlusive artery disease

The present invention provides compounds having formula (I) or (II): 

Small molecule modulators of cytokine activity

Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is: 

Sulfonamide peri-substituted bicyclics for occlusive artery disease

The present invention involves a process for preparing substituted indoles, such as DTSI involving two sequential cross-coupling reactions.

Process for preparing 7-(acryloyl)indoles

The present invention relates to anti-tumor compounds, compositions and methods. In particular, the invention relates to indolocarbazole analogues of the following general formulas that inhibit topoisomerase I activity

Indolocarbazole anticancer agents and methods of using them

Substantially purified antiviral biflavanoids robustaflavone, hinokiflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a, and GB-2a are provided. Antiviral biflavanoid derivatives and salt forms thereof, e.g., robustaflavone tetrasulfate potassium salt, and methods for preparing the same are also disclosed. Pharmaceutical compositions which include the antiviral biflavanoids, derivatives or salts thereof are also provided alone or in combination with at least one antiviral agent such as 3TC. Also disclosed is an improved method for obtaining substantially pure robustaflavone from plant material. The biflavanoid compounds, derivatives or salts thereof of the invention may be used in a method for treating and/or preventing viral infections caused by viral agents such as influenza, e.g., influenza A and B; hepatitis, e.g., hepatitis B; human immunodeficiency virus, e.g., HIV-1; Herpes viruses (HSV-1 and HSV-2); Varicella Zoster virus (VZV); and measles. For instance, semi-synthetic hexa-O-acetate and hexa-O-methyl ether derivatives of robustaflavone have been found to be effective in a method for treating or preventing hepatitis B viral infections. Compositions which include these robustaflavone derivatives along with methods for preparing and using the same are also provided. These compositions may be used alone or in combination with at least one antiviral agent such as 3TC.

Biflavanoids and derivatives thereof as antiviral agents

Robustaflavone, intermediates and analogues thereof and a method for synthesizing the same are provided. The method involves constructing apigenin ethers containing functionalities at the 6- and 3&prime;-positions which could be cross-coupled using transition metal catalysis. The method also involves development of a regioselective iodination of an apigenin derivative at the 6-position, formation of an apigenin 3&prime;-boronate using a palladium-catalyzed exchange of the corresponding 3&prime;-iodide with a diboron reagent. Finally, Suzuki coupling to form the sterically congested 6-3&prime;&Prime; biaryl bond of robustaflavone provides access to the desired biflavanoid system. Robustaflavone intermediates and analogues may be used to prepare analogues of other biflavanoids such as hinokifavone, rhusflavone and succedaneaflavone.

Robustaflavone, intermediates and analogues and method for preparation thereof

Substantially purified antiviral biflavanoids robustaflavone, hinokiflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a, and GB-2a are provided. Antiviral biflavanoid derivatives and salt forms thereof, e.g., robustaflavone tetrasulfate potassium salt, and methods for preparing the same are also disclosed. Pharmaceutical compositions which include the antiviral biflavanoids, derivatives or salts thereof are also provided. Also disclosed is an improved method for obtaining substantially pure robustaflavone from plant material. The biflavanoid compounds, derivatives or salts thereof of the invention may be used in a method for treating and/or preventing viral infections caused by viral agents such as influenza, e.g., influenza A and B; hepatitis, e.g., hepatitis B; human immunodeficiency virus, e.g., HIV-1; Herpes viruses (HSV-1 and HSV-2); Varicella Zoster virus (VZV); and measles.

Growing community of inventors

LaGrange, IL, United States of America

David E Zembower